scholarly article | Q13442814 |
P356 | DOI | 10.1177/2042018816676239 |
P8608 | Fatcat ID | release_hjxzgmi66feuroboorpgkfruii |
P932 | PMC publication ID | 5298360 |
P698 | PubMed publication ID | 28203358 |
P2093 | author name string | John Doupis | |
Spyridoula Glykofridi | |||
Vasileios Andrianesis | |||
P2860 | cites work | T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes | Q78238839 |
Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis | Q80984741 | ||
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects | Q84856868 | ||
Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects | Q85428079 | ||
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration | Q85674886 | ||
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial | Q87809056 | ||
The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat | Q88214242 | ||
The fundamental drivers of the obesity epidemic | Q22242406 | ||
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 | ||
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial | Q27301948 | ||
SGLT2 Inhibitors May Predispose to Ketoacidosis | Q28081173 | ||
The sodium/glucose cotransport family SLC5 | Q28204259 | ||
Active sugar transport in health and disease | Q28283298 | ||
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models | Q28732080 | ||
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar | Q33612741 | ||
The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? | Q33778918 | ||
Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus | Q33785128 | ||
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications | Q34120717 | ||
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial | Q34153496 | ||
A Review on the Relationship between SGLT2 Inhibitors and Cancer. | Q34181385 | ||
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes | Q34227891 | ||
Tofogliflozin: first global approval | Q34420901 | ||
SGLT2 mediates glucose reabsorption in the early proximal tubule. | Q34457264 | ||
Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density | Q34535894 | ||
Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? | Q34579919 | ||
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise | Q34646948 | ||
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
Molecular physiology of sodium-glucose cotransporters | Q34724942 | ||
Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus | Q34876148 | ||
Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials | Q35068181 | ||
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial | Q35179843 | ||
Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose | Q35184196 | ||
Renal hyperfiltration related to diabetes mellitus and obesity in human disease | Q35673442 | ||
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. | Q35968414 | ||
Phlorizin: a review | Q35995949 | ||
Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study' | Q36073447 | ||
Glomerular hyperfiltration and renal disease progression in type 2 diabetes | Q36249519 | ||
Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus | Q36312587 | ||
Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an update | Q36435496 | ||
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes | Q36782790 | ||
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Q36845771 | ||
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes | Q36926197 | ||
Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells | Q36977366 | ||
Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study | Q37022903 | ||
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes | Q37139427 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. | Q37219076 | ||
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment | Q37319128 | ||
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes | Q37331262 | ||
Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. | Q37387010 | ||
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. | Q37575455 | ||
Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor | Q37589626 | ||
Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. | Q37645623 | ||
Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes | Q37679810 | ||
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control | Q37679893 | ||
The protein family of glucose transport facilitators: It's not only about glucose after all. | Q37704272 | ||
The clinical significance of hyperfiltration in diabetes | Q37760090 | ||
Biology of human sodium glucose transporters | Q37870037 | ||
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. | Q37940036 | ||
SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus | Q38077305 | ||
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors | Q38196149 | ||
Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport | Q38201162 | ||
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes | Q38205581 | ||
Arterial stiffness: insights from Framingham and Iceland | Q38282226 | ||
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus | Q38439475 | ||
Transforming growth factor-beta1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells | Q40276214 | ||
The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies | Q40325056 | ||
Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes | Q40328483 | ||
The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells | Q40561968 | ||
Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. | Q41015653 | ||
TGF-beta 1 dissociates human proximal tubule cell growth and Na(+)-H+ exchange activity. | Q42455935 | ||
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial | Q42977455 | ||
Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus | Q43199877 | ||
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. | Q43755014 | ||
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus | Q44007780 | ||
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial | Q44251536 | ||
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin | Q44653784 | ||
Long-term outcome of renal glucosuria type 0: the original patient and his natural history | Q45010378 | ||
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes | Q45348074 | ||
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia | Q45442620 | ||
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study | Q46223922 | ||
PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose | Q46484275 | ||
Screening for kidney disease in adults with diabetes | Q46570776 | ||
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. | Q46847425 | ||
Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor | Q46986653 | ||
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment | Q47998377 | ||
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. | Q50448714 | ||
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. | Q51304272 | ||
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. | Q51337136 | ||
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. | Q51362851 | ||
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. | Q51372081 | ||
Differences in active and passive glucose transport along the proximal nephron | Q52734694 | ||
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. | Q53084508 | ||
Pathologic classification of diabetic nephropathy. | Q55052603 | ||
Luseogliflozin: First Global Approval | Q57485821 | ||
Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0) | Q68986451 | ||
Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs | Q69490075 | ||
Further studies of proximal tubular brush border membrane D-glucose transport heterogeneity | Q70640377 | ||
Glomerular hemodynamics in experimental diabetes mellitus | Q70801958 | ||
Is renal glycosuria a benign condition? | Q71153660 | ||
The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy | Q72007027 | ||
Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies | Q72925253 | ||
Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption | Q73253331 | ||
P433 | issue | 5-6 | |
P304 | page(s) | 212-228 | |
P577 | publication date | 2016-11-11 | |
P1433 | published in | Therapeutic advances in endocrinology and metabolism | Q26853790 |
P1476 | title | The renal effects of SGLT2 inhibitors and a mini-review of the literature | |
P478 | volume | 7 |
Q90402115 | Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases |
Q48015498 | Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes |
Q47795925 | Epithelial Organization: The Gut and Beyond |
Q57688763 | Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease |
Q89143763 | Medication Safety Principles and Practice in CKD |
Q91868121 | Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages |
Q90603547 | Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI |
Q33696974 | SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease |